Answers are grounded in this paper and cite their sources.
Therapeutic inertia is a prevalent problem in people with type 2 diabetes in primary care and affects clinical outcomes. It arises from a complex interplay of patient-, clinician-, and health system-related factors. Ultimately, clinical practice guidelines have not made an impact on improving glycemic targets over the past decade. A more proactive approach, including focusing on optimal combination agents for early glycemic durability, may reduce therapeutic inertia and improve clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: